Compare AFLAC Incorporated (AFL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Illumina, Inc. — how do they compare? AFLAC Incorporated trades at $120.98 (market cap $60.70B), while Illumina, Inc. trades at $191.08 (market cap $29.12B). The key difference: AFLAC Incorporated is far larger — about 2.1× Illumina, Inc.'s market cap, and AFLAC Incorporated pays a 2.02% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| AFL | ILMN | |
|---|---|---|
Market Cap | $60.70B | $29.12B |
Sector | Financials | Health |
52-Week High | $129.55 | $205.10 |
52-Week Low | $103.55 | $91.00 |
Enterprise Value | $70.65B | $30.48B |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $121.09, down 0.7% on the day, with a bullish overall technical signal but bearish moving averages and oscillators. The stock shows strong profitability with a 26.59% net income margin and 16.91% ROE, though recent quarters have seen EPS misses. Revenue declined to $17.36B in 2025, with net income of $3.65B. Recent news highlights AFL's rebranding of network services and ongoing dividend commitments.
Outlook is mixed; solid fundamentals and a 43-year dividend growth history support income investors, but near-term headwinds include revenue pressure in Japan and FX impacts. Analyst consensus is cautious with a $118 price target below current levels, suggesting limited upside amid execution risks and competitive pressures.
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
